These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 17975904)

  • 1. Activity of rat cytosolic thioredoxin reductase is strongly decreased by trans-[bis(2-amino-5- methylthiazole)tetrachlororuthenate(III)]: first report of relevant thioredoxin reductase inhibition for a ruthenium compound.
    Mura P; Camalli M; Bindoli A; Sorrentino F; Casini A; Gabbiani C; Corsini M; Zanello P; Rigobello MP; Messori L
    J Med Chem; 2007 Nov; 50(24):5871-4. PubMed ID: 17975904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substrate and inhibitor specificities differ between human cytosolic and mitochondrial thioredoxin reductases: Implications for development of specific inhibitors.
    Rackham O; Shearwood AM; Thyer R; McNamara E; Davies SM; Callus BA; Miranda-Vizuete A; Berners-Price SJ; Cheng Q; Arnér ES; Filipovska A
    Free Radic Biol Med; 2011 Mar; 50(6):689-99. PubMed ID: 21172426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of calcium ions on the cytosolic and mitochondrial thioredoxin reductase.
    Rigobello MP; Vianello F; Folda A; Roman C; Scutari G; Bindoli A
    Biochem Biophys Res Commun; 2006 May; 343(3):873-8. PubMed ID: 16564501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emerging protein targets for anticancer metallodrugs: inhibition of thioredoxin reductase and cathepsin B by antitumor ruthenium(II)-arene compounds.
    Casini A; Gabbiani C; Sorrentino F; Rigobello MP; Bindoli A; Geldbach TJ; Marrone A; Re N; Hartinger CG; Dyson PJ; Messori L
    J Med Chem; 2008 Nov; 51(21):6773-81. PubMed ID: 18834187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-function relationships within Keppler-type antitumor ruthenium(III) complexes: the case of 2-aminothiazolium[trans-tetrachlorobis(2-aminothiazole)ruthenate(III)].
    Mura P; Piccioli F; Gabbiani C; Camalli M; Messori L
    Inorg Chem; 2005 Jul; 44(14):4897-9. PubMed ID: 15998012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitochondrial thioredoxin reductase inhibition, selenium status, and Nrf-2 activation are determinant factors modulating the toxicity of mercury compounds.
    Branco V; Godinho-Santos A; Gonçalves J; Lu J; Holmgren A; Carvalho C
    Free Radic Biol Med; 2014 Aug; 73():95-105. PubMed ID: 24816296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols.
    Hickey JL; Ruhayel RA; Barnard PJ; Baker MV; Berners-Price SJ; Filipovska A
    J Am Chem Soc; 2008 Sep; 130(38):12570-1. PubMed ID: 18729360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth.
    McNaughton M; Engman L; Birmingham A; Powis G; Cotgreave IA
    J Med Chem; 2004 Jan; 47(1):233-9. PubMed ID: 14695837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and antitumor activity of triazolium-bis(triazole)-tetrachlororuthenate (III) and bistriazolium-triazolepentachlororuthenate (III). Two representatives of a new class of inorganic antitumor agents.
    Keppler BK; Balzer W; Seifried V
    Arzneimittelforschung; 1987 Jul; 37(7):770-1. PubMed ID: 3675670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sublethal concentrations of diverse gold compounds inhibit mammalian cytosolic thioredoxin reductase (TrxR1).
    Omata Y; Folan M; Shaw M; Messer RL; Lockwood PE; Hobbs D; Bouillaguet S; Sano H; Lewis JB; Wataha JC
    Toxicol In Vitro; 2006 Sep; 20(6):882-90. PubMed ID: 16510263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of mammalian thioredoxin reductase by black tea and its constituents: implications for anticancer actions.
    Du Y; Wu Y; Cao X; Cui W; Zhang H; Tian W; Ji M; Holmgren A; Zhong L
    Biochimie; 2009 Mar; 91(3):434-44. PubMed ID: 19059456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis, characterization, and in vitro evaluation of a potentially selective anticancer, mixed-metal [ruthenium(III)-platinum(II)] trinuclear complex.
    Herman A; Tanski JM; Tibbetts MF; Anderson CM
    Inorg Chem; 2008 Jan; 47(1):274-80. PubMed ID: 18062685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug.
    Zhang X; Selvaraju K; Saei AA; D'Arcy P; Zubarev RA; Arnér ES; Linder S
    Biochimie; 2019 Jul; 162():46-54. PubMed ID: 30946948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transgenic mouse models for the vital selenoenzymes cytosolic thioredoxin reductase, mitochondrial thioredoxin reductase and glutathione peroxidase 4.
    Conrad M
    Biochim Biophys Acta; 2009 Nov; 1790(11):1575-85. PubMed ID: 19433132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel ruthenium(II) arene based intercalator with potent anticancer activity.
    Ruiz J; Vicente C; de Haro C; Bautista D
    Dalton Trans; 2009 Jul; (26):5071-3. PubMed ID: 19562164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gold(III) compounds as anticancer agents: relevance of gold-protein interactions for their mechanism of action.
    Casini A; Hartinger C; Gabbiani C; Mini E; Dyson PJ; Keppler BK; Messori L
    J Inorg Biochem; 2008 Mar; 102(3):564-75. PubMed ID: 18177942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osmocenyl-tamoxifen derivatives target the thioredoxin system leading to a redox imbalance in Jurkat cells.
    Scalcon V; Top S; Lee HZ; Citta A; Folda A; Bindoli A; Leong WK; Salmain M; Vessières A; Jaouen G; Rigobello MP
    J Inorg Biochem; 2016 Jul; 160():296-304. PubMed ID: 27130146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid based nanovectors containing ruthenium complexes: a potential route in cancer therapy.
    Vaccaro M; Del Litto R; Mangiapia G; Carnerup AM; D'Errico G; Ruffo F; Paduano L
    Chem Commun (Camb); 2009 Mar; (11):1404-6. PubMed ID: 19259602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel electrophilic amides amenable by the Ugi reaction perturb thioredoxin system via thioredoxin reductase 1 (TrxR1) inhibition: Identification of DVD-445 as a new lead compound for anticancer therapy.
    Jovanović M; Zhukovsky D; Podolski-Renić A; Domračeva I; Žalubovskis R; Senćanski M; Glišić S; Sharoyko V; Tennikova T; Dar'in D; Pešić M; Krasavin M
    Eur J Med Chem; 2019 Nov; 181():111580. PubMed ID: 31400708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights into the strong in-vitro anticancer effects for bis(triphenylphosphane)iminium compounds having perchlorate, tetrafluoridoborate and bis(chlorido)argentate anions.
    Folda A; Scalcon V; Ghazzali M; Jaafar MH; Khan RA; Casini A; Citta A; Bindoli A; Rigobello MP; Al-Farhan K; Alsalme A; Reedijk J
    J Inorg Biochem; 2015 Dec; 153():346-354. PubMed ID: 26384162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.